Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness

被引:119
作者
Shariat, Shahrokh F.
Zlotta, Alexandre R.
Ashfaq, Raheela
Sagalowsky, Arthur I.
Lotan, Yair
机构
[1] Univ Texas, SW Med Ctr, Dept Urol, Dallas, TX 75216 USA
[2] Univ Toronto, Mt Sinai Hosp, Dept Urol, Toronto, ON M5G 1X5, Canada
[3] Univ Toronto, Princess Margaret Hosp, Dept Urol, Toronto, ON, Canada
[4] Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75216 USA
关键词
p53; p21; p27; retinoblastoma; progression; bladder cancer;
D O I
10.1038/modpathol.3800757
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The aim of this study was to evaluate the association between p53, p21, p27 and Rb expression, alone or in combination, with pathological features and clinical outcomes of urothelial carcinoma of the bladder. Immunohistochemical staining for p53, p21, p27 and pRB was performed on tissue microarrays comprising normal urothelium from nine controls, transurethral resection specimens from 74 patients with Ta, Tis and/or T1 bladder urothelial carcinoma, radical cystectomy specimens from 226 consecutive urothelial carcinoma patients, and lymph nodes with tumor invasion from 50 of the 226 cystectomy patients. All nine controls had normal status of biomarkers. The proportion of biomarkers alterations was highest in lymph node metastases. p53, pRB and p27 were associated with pathologic stage, lymphovascular invasion and lymph node metastases (P-values <= 0.050). Each biomarker alone, each combination of two biomarkers and the number of altered biomarkers were all independently associated with disease recurrence and bladder cancer-specific death (P-values <= 0.046). In patients with organ-confined disease, p53, p21 and p27 were independently associated with disease recurrence and bladder cancer-specific death (P-values <= 0.046). There was a good but not perfect concordance in the expression of biomarkers between matched transurethral resection and cystectomy specimens (n = 22; concordance rates: 77-86%) and between matched lymph node and cystectomy specimens (n = 50, 70-92%). In conclusion, p53, p21, p27 and pRB have a cooperative/ synergistic role in the biologic behavior of bladder urothelial carcinoma. In contrast to the use of single biological markers, evaluation of their combined status may improve prognostic models and help identify patients who might benefit from adjuvant therapies and in decision-making.
引用
收藏
页码:445 / 459
页数:15
相关论文
共 27 条
[1]  
Bauer KD, 2000, CLIN CANCER RES, V6, P3552
[2]   Level of retinoblastoma protein expression correlates with p16 (MTS-1/INK4A/CDKN2) status in bladder cancer [J].
Benedict, WF ;
Lerner, SP ;
Zhou, J ;
Shen, XH ;
Tokunaga, H ;
Czerniak, B .
ONCOGENE, 1999, 18 (05) :1197-1203
[3]   Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma [J].
Chatterjee, SJ ;
Datar, R ;
Youssefzadeh, D ;
George, B ;
Goebell, PJ ;
Stein, JP ;
Young, LL ;
Shi, SR ;
Gee, C ;
Groshen, S ;
Skinner, DG ;
Cote, RJ .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (06) :1007-1013
[4]   P53 MUTATIONS IN HUMAN BLADDER-CANCER - GENOTYPIC VERSUS PHENOTYPIC PATTERNS [J].
CORDONCARDO, C ;
DALBAGNI, G ;
SAEZ, GT ;
OLIVA, MR ;
ZHANG, ZF ;
ROSAI, J ;
REUTER, VE ;
PELLICER, A .
INTERNATIONAL JOURNAL OF CANCER, 1994, 56 (03) :347-353
[5]   ALTERED EXPRESSION OF THE RETINOBLASTOMA GENE-PRODUCT - PROGNOSTIC INDICATOR IN BLADDER-CANCER [J].
CORDONCARDO, C ;
WARTINGER, D ;
PETRYLAK, D ;
DALBAGNI, G ;
FAIR, WR ;
FUKS, Z ;
REUTER, VE .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1992, 84 (16) :1251-1256
[6]  
CordonCardo C, 1997, CANCER RES, V57, P1217
[7]  
Cote RJ, 1998, CANCER RES, V58, P1090
[8]   Loss of cell cycle regulators p27Kip1 and cyclin E in transitional cell carcinoma of the bladder correlates with tumor grade and patient survival [J].
Del Pizzo, JJ ;
Borkowski, A ;
Jacobs, SC ;
Kyprianou, N .
AMERICAN JOURNAL OF PATHOLOGY, 1999, 155 (04) :1129-1136
[9]   Immunohistochemical localization and semi-quantitation of hepatic tamoxifen-DNA adducts in rats exposed orally to tamoxifen [J].
Divi, RL ;
Dragan, YP ;
Pitot, HC ;
Poirier, MC .
CARCINOGENESIS, 2001, 22 (10) :1693-1699
[10]  
ESRIG D, 1993, AM J PATHOL, V143, P1389